Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | FHIT | P49789 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963136 | 0.84 | GAA (0.69) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL14340734 | 0.83 | ALDH1A1 (0.56) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1973680 | 0.83 | GAA (1.00) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5123339 | 0.83 | GAA (0.67) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL2181959 | 0.81 | ALDH1A1 (0.57) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL7852072 | 0.81 | GAA (0.65) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL810348 | 0.80 | GAA (0.77) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3647679 | 0.80 | GAA (0.63) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5128149 | 0.80 | GAA (0.63) | GAAMAPK1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL12204918 | 0.80 | GAA (0.63) | GAAMAPK1ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118619968-A | Dihydrothienopyrimidino pyrido indol-4-one derivative and application thereof | 新疆工程学院 | 2024-09-10 | — | — | CN | disclosed |
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4219507-A2 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-11648253-B2 | Thienopyrimidinone NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-05-16 | — | — | US | disclosed |
| WO-1996022991-A1 | BICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-08-01 | — | — | WO | disclosed |
| US-5521181-A | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists | ABBOTT LABORATORIES (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0234557-B1 | 3-(1H-Tetrazol-5-yl)thieno[2,3-d]pyrimidin-4(3H)-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-11-28 | — | — | EP | disclosed |
| US-4761474-A | 3-(1H-tetrazol-5-yl)thieno[2,3-d]pyrimidin-4(3H)-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-02 | — | — | US | disclosed |
| US-4692461-A | PLANT PROTECTION | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
| EP-0234557-A1 | 3-(1H-Tetrazol-5-yl)thieno[2,3-d]pyrimidin-4(3H)-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0224140-A1 | Thienyl urea derivatives | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
| US-4079060-A | Thienopyridine-carboxylic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1978-03-14 | — | — | US | disclosed |
| US-3997545-A | Thienopyridine-carboxylic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-12-14 | — | — | US | disclosed |
| US-3951989-A | Thienopyridine-carboxylic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | GAA 1755/4885MAPK1 2860/4885ALDH1A1 621/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | GAA 1755/4885MAPK1 2860/4885ALDH1A1 621/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | GAA 1755/4885MAPK1 2860/4885ALDH1A1 621/4885 |
| US-11648253-B2 | Thienopyrimidinone NMDA receptor modulators and uses thereof | GRIN1, GRIN2C, GRIN3A | GAA 4006/4885MAPK1 3534/4885ALDH1A1 1649/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | GAA 1366/4885MAPK1 1820/4885ALDH1A1 4172/4885 |
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | GAA 82/4885MAPK1 2900/4885ALDH1A1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.